Iron chelators as mitophagy agents: Potential and limitations
| Autoři | |
|---|---|
| Rok publikování | 2024 |
| Druh | Článek v odborném periodiku |
| Časopis / Zdroj | BIOMEDICINE & PHARMACOTHERAPY |
| Fakulta / Pracoviště MU | |
| Citace | |
| www | https://www.sciencedirect.com/science/article/pii/S0753332224012927?via%3Dihub |
| Doi | http://dx.doi.org/10.1016/j.biopha.2024.117407 |
| Klíčová slova | Mitophagy; Iron heomeostais; Iron chelators; Cancer; Neurodegenerative diseases; Cardiovascular diseases |
| Přiložené soubory | |
| Popis | Mitochondrial autophagy (mitophagy) is very important process for the maintenance of cellular homeostasis, functionality and survival. Its dysregulation is associated with high risk and progression numerous serious diseases (e.g., oncological, neurodegenerative and cardiovascular ones). Therefore, targeting mitophagy mechanisms is very hot topic in the biological and medicinal research. The interrelationships between the regulation of mitophagy and iron homeostasis are now becoming apparent. In short, mitochondria are central point for the regulation of iron homeostasis, but change in intracellular cheatable iron level can induce/repress mitophagy. In this review, relationships between iron homeostasis and mitophagy are thoroughly discussed and described. Also, therapeutic applicability of mitophagy chelators in the context of individual diseases is comprehensively and critically evaluated. |
| Související projekty: |
|